Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 101 - 104 of 104

Insights

ABSTRACT: Glioblastoma remains an incurable brain cancer. Drugs developed in the past 20 years have not improved the prognosis for patients, necessitating the development of new treatments. We have previously reported the therapeutic potential of the quinoline methanol Vacquinol-1 (1) that targets glioblastoma cells and induces cell death by catastrophic vacuolization.

Insights

The many challenges faced by the pharmaceutical industry throughout the supply chain, including fraud and counterfeit medicines, have led to international serialisation requirements in the U.S and Europe. With this in mind, CDMOs have a lot to consider with the new track and trace regulations.

Insights

Abstract: 6H-1,3,4-Thiadiazines are a promising class of non-aromatic heterocycles for the agricultural and pharmaceutical industry. Although known for a long time, they have not received widespread attention, in part due to their cumbersome synthesis.

Insights

The risk of failure and cost invovled with developing new pharmaceutical products can be significantly reduced by using existing active ingredients in the development process and choosing the right partner for the development of the specific requirements of microtablets is crucial.